Related Experiment Video
Updated: Aug 10, 2026
10:49
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 19, 2013
Hairy cell leukemia--results with alpha interferon therapy
S Pai1, S C Shinde, T K Saikia
1Dept. of Medical Oncology, Tata-Memorial Hospital, Parel, Mumbai.
The Journal of the Association of Physicians of India
|September 22, 2000
Summary
Recombinant interferon alpha 2a offers long-term remission for hairy cell leukemia (HCL) patients in India. This study shows an 88.9% response rate and 83% disease-free survival, with cost being a consideration.
Area of Science:
- Hematology
- Oncology
Background:
- Hairy cell leukemia (HCL) is a rare lymphoproliferative disorder with evolving treatment landscapes.
- Optimal HCL treatment remains debated despite available options.
- Recombinant interferon is the primary first-line treatment in India due to availability.
Purpose of the Study:
- To evaluate the efficacy of interferon alpha 2a in achieving long-term remissions in HCL patients.
- To report the experience of treating HCL with interferon alpha 2a in an Indian setting.
Main Methods:
- Retrospective analysis of 35 HCL cases.
- Treatment of 19 cases with interferon alpha 2a.
- Dosage: 3 million units subcutaneously daily for at least 6 months.
- Evaluation of overall response and disease-free survival.
Main Results:
- Overall response rate of 88.9% in 18 evaluable cases.
- Disease-free survival of 83% with a median follow-up of 31 months.
- Long-term remissions were observed.
Conclusions:
- Interferon alpha 2a can achieve good long-term remission in HCL.
- The recommended dosage is 3 million units daily for a minimum of 6 months.
- Treatment cost remains a significant barrier.
